modelFludrocortisoneAndAntiin
Extends from Pharmacolibrary.Drugs.ATC.S.S03CA05.
Information
| name: | FludrocortisoneAndAntiinfectives | |
| ATC code: | S03CA05 | route: | ocular |
| compartments: | 1 | |
| dosage: | 0.1 | mg |
| volume of distribution: | 0.5 | L |
| clearance: | 10 | L/h |
| other parameters in model implementation | ||
Fludrocortisone is a synthetic corticosteroid with potent mineralocorticoid properties and moderate glucocorticoid effects, used mainly for the treatment of adrenocortical insufficiency (Addison's disease), salt-losing adrenogenital syndrome, and other conditions requiring mineralocorticoid replacement. The ATC code S03CA05 refers to ocular antibiotic and corticosteroid combination products. This specific combination preparation (fludrocortisone and antiinfectives) is not widely described in major pharmacokinetic publications, is not commonly approved today, and information is limited.
Pharmacokinetics
No published studies on pharmacokinetics of fludrocortisone and antiinfective combination with ATC code S03CA05. Estimates are provided based on fludrocortisone systemic parameters and considering topical (ocular) administration, which generally results in minimal systemic exposure.
References
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)